1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Latvia Pharmaceuticals and Healthcare Report Q1 2016

Latvia Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 85 pages

Includes 3 FREE quarterly updates

BMI View: The development of Latvia's market will be shaped by an increased emphasis on generic drugs;an implication of fiscal austerity measures As a result, despite its transparent regulatory policies andbusiness-friendly operating environment, the Latvian pharmaceutical market will continue to remain amodest prospect for drugmakers Exports will also be impacted by regional tensions

Headline Expenditure Projections

- Pharmaceuticals: EUR319mn (USD428mn) in 2014 to EUR338mn (USD372mn) in 2015; +58% inlocal currency terms and -132% in US dollar terms Forecast unchanged from previous quarter

- Healthcare: EUR970mn (USD130bn) in 2014 to EUR101bn (USD111bn) in 2015; +40% in localcurrency terms and -147% in US dollar terms Forecast unchanged on previous quarter

Table Of Contents

Latvia Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Latvia 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Latvia 2011-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 18
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 20
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 22
OTC Medicine Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 24
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Latvia 2013-2019) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Latvia 2013-2019) 26
Pharmaceuticals and Healthcare Risk/Reward Index 27
Central And Eastern Europe Risk/Reward Index - Q1 2016 27
Latvia Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Regional Collaboration 37
Intellectual Property 38
Pricing Regime 38
Reimbursement Regime 40
Market Overview 42
Market Overview 42
Epidemiology 43
Table: Leading Causes of Death, 1990-2010 43
Table: New Cases of Cancer, 2004-2010 45
Table: Cumulative Reported Cases of HIV and AIDS, 2000-2010 47
Healthcare Sector 47
Healthcare Sector Funding 48
Healthcare Provision 49
Table: Healthcare Resources (Latvia 2009-2014) 49
Table: Hospitals and Beds, 2006-2010 50
Table: Hospital Beds by Specialty, 2004-2010 50
Table: Healthcare Personnel (Latvia 2009-2014) 52
Table: Healthcare Activity (Latvia 2009-2014) 52
Research and Development 52
Biotechnology 53
Clinical Trials 55
Competitive Landscape 56
Research-Based Industry 56
Table: Licences Issued To Companies Engaged In Pharmaceutical Manufacturing And Distribution, 2007-2011 56
Table: Medicines Consumption According To Marketing Authorisation Holders (turnover in LVL) 57
Table: Table: Multinational Market Activity 58
Generic Drugmakers 59
Pharmaceutical Distribution 59
Table: Wholesale Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008 60
Table: Wholesalers Market Share, 2010 (%) 62
Pharmaceutical Retail Sector 62
Table: Pharmacy Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008 63
Table: Licences Issued To Pharmacies 64
Company Profile 66
Grindeks 66
Olainfarm 70
Demographic Forecast 74
Table: Population Headline Indicators (Latvia 1990-2025) 75
Table: Key Population Ratios (Latvia 1990-2025) 75
Table: Urban/Rural Population and Life Expectancy (Latvia 1990-2025) 76
Table: Population By Age Group (Latvia 1990-2025) 76
Table: Population By Age Group % (Latvia 1990-2025) 77
Glossary 79
Methodology 81
Pharmaceutical Expenditure Forecast Model 81
Healthcare Expenditure Forecast Model 81
Notes On Methodology 82
Risk/Reward Index Methodology 83
Index Overview 84
Table: Pharmaceutical Risk/Reward Index Indicators 84
Indicator Weightings 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.